“…COMPASS Pathways (CMPS)… Morgan Stanley analyst Vikram Purohit, who covers the stock, sees CMPS as presenting a compelling risk-reward opportunity. He highlights the company’s leading clinical program… To this end, Purohit rates CMPS shares an Overweight (i.e. Buy), and his $23 price… Continue Reading…